EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Graphite Bio's enterprise value is $1,112.46 Mil.
Graphite Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Graphite Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Graphite Bio's EV-to-Revenue or its related term are showing as below:
GRPH's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.95 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2024-05-15), Graphite Bio's stock price is $3.18.
Graphite Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Graphite Bio's PS Ratio for today is .
Graphite Bio EV-to-Revenue Historical Data
The historical data trend for Graphite Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Graphite Bio's EV-to-Revenue
For the Biotechnology subindustry, Graphite Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Graphite Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Graphite Bio's EV-to-Revenue falls into.
Graphite Bio's current Enterprise Value is $1,112.46 Mil.
Graphite Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio's share price for today is $3.18.
Graphite Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Graphite Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 